Investigational drug · Phase 3
AL2846
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Cancer, Differentiated Thyroid Cancer, Advanced Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
10
Any phase or sponsor naming "AL2846"
First trial start
2023
Feb 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AL2846", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thyroid Cancer
- Differentiated Thyroid Cancer
- Advanced Lung Cancer
- Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Thyroid cancer · Oncology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "AL2846" as an intervention, largest first.
- Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.Pivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05922345 · 518 participants (planned) · Start Jun 8, 2023 · Primary completion Aug 2025
Drug: TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules; TQB2450 placebo, docetaxel injection, AL2846 matching placebo · For: Non-small Cell Lung Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 71 sites in all
- A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid CarcinomaPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06860971 · 144 participants (planned) · Start Apr 18, 2025 · Primary completion Jan 2027
Drug: AL2846 Capsules; AL2846 Placebo · For: Thyroid Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 35 sites in all
- A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid TumorsStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06116240 · 135 participants (planned) · Start Sep 2, 2022 · Primary completion Dec 2023
Drug: TQB2450 injection; AL2846 capsule and 2 more · For: Solid Tumor
Sites: Beijing, China; Jiangmen, China; Baoding, China · 12 sites in all
- A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone MetastasisStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04325776 · 60 participants (planned) · Start Sep 24, 2020 · Primary completion May 2021
Drug: AL2846; Zoledronic Acid Injection · For: Bone Metastatic Non-small Cell Lung Cancer
Sites: Hefei, China; Zhengzhou, China; Changchun, China · 8 sites in all
- A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal CancerStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04337879 · 56 participants (planned) · Start Jul 20, 2020 · Primary completion Dec 31, 2020
Drug: AL2846; Calcium folate and 3 more · For: Advanced Colorectal Cancer
Sites: Shengyang, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06278493 · 34 participants · Start Aug 23, 2018 · Primary completion Oct 25, 2021
Drug: AL2846 capsules; Gemzar · For: Pancreatic Cancer
Sites: Tianjin, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05745363 · 33 participants · Start Feb 24, 2023 · Primary completion Nov 13, 2025
Drug: AL2846 capsule · For: Differentiated Thyroid Cancer
Sites: Guilin, China; Changsha, China; Nanchang, China · 4 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05815862 · 29 participants · Start Feb 15, 2023 · Primary completion Aug 20, 2025
Drug: AL2846 capsule · For: Advanced Lung Cancer; Ovarian Cancer
Sites: Changsha, China; Yangzhou, China; Shanghai, China · 4 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05011019 · 22 participants · Start Sep 7, 2021 · Primary completion Feb 2, 2024
Drug: AL2846 capsules · For: Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors
Sites: Shanghai, China
- A Study of AL2846 on Tolerance and PharmacokineticsStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT02779699 · 20 participants (planned) · Start May 2016 · Primary completion Oct 2020
Drug: AL2846 · For: Advanced Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- AL2846, a Novel Multi-Kinase Inhibitor, for Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer: Exploratory Clinical Results From the Phase Ib Study.
Shi F, Chai W, Yang H, et al. · Clin Cancer Res 2026
- Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer.
Liu R, Ji Z, Wang X, et al. · Invest New Drugs 2025
- Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
Ning T, Li D, Deng T, et al. · Cancer 2024
Also in development for Thyroid Cancer
- XP-102Phase 21 trial
Xynomic Pharmaceuticals, Inc. · Cancer, BRAF V600 Mutation, Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.